Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 8, JonesTrading analyst Soumit Roy reduced the firm’s price target on Beam Therapeutics Inc. (NASDAQ:BEAM) from $34 to $25, while maintaining a Buy rating on the stock.
The analyst noted that the company has been making good progress with its clinical trials, highlighting its BEAM-302 Phase 1/2 trial for AATD, where 17 patients have been dosed, with data expected soon. Moreover, Beam Therapeutics Inc. is also preparing updated results from its BEACON Phase 1/2 trial with BEAM-101 by the end of 2025 and also plans to start a Phase 1 trial for BEAM-103.
A patient undergoing MRI scanning to effectively diagnose Liver Diseases.
Talking about the financial position of the company, the analyst noted that the company has about $1.15 billion in cash, which gives it a solid runway till 2028. Lastly, Roy noted that the reduced price target reflects a valuation based on a different valuation model, which sets the stock price at $25.
Beam Therapeutics Inc. develops precise genetic medicines using base editing technology. This method allows the company to make exact single-base changes in DNA without causing harmful breaks.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
